 Anna Bruckner
Concepts (472)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 32 | 2025 | 68 | 8.010 |
Why?
| | Epidermolysis Bullosa Dystrophica | 15 | 2025 | 42 | 2.990 |
Why?
| | Hemangioma | 9 | 2016 | 46 | 2.490 |
Why?
| | Dermatology | 8 | 2025 | 128 | 2.420 |
Why?
| | Skin Neoplasms | 12 | 2024 | 847 | 1.680 |
Why?
| | Collagen Type VII | 5 | 2025 | 28 | 1.510 |
Why?
| | Epidermolysis Bullosa Simplex | 4 | 2026 | 14 | 1.350 |
Why?
| | Skin | 11 | 2026 | 758 | 1.180 |
Why?
| | Acne Vulgaris | 2 | 2022 | 25 | 1.110 |
Why?
| | Organic Chemicals | 3 | 2025 | 127 | 1.080 |
Why?
| | Bandages | 1 | 2025 | 42 | 0.900 |
Why?
| | Dermatologic Agents | 3 | 2025 | 68 | 0.810 |
Why?
| | Lymphatic Abnormalities | 2 | 2014 | 20 | 0.760 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2925 | 0.750 |
Why?
| | Ichthyosis, Lamellar | 3 | 2022 | 9 | 0.720 |
Why?
| | Gentamicins | 1 | 2022 | 51 | 0.710 |
Why?
| | Humans | 107 | 2026 | 144957 | 0.710 |
Why?
| | Child | 46 | 2025 | 22657 | 0.700 |
Why?
| | Infant | 27 | 2025 | 10039 | 0.660 |
Why?
| | Chilblains | 1 | 2020 | 3 | 0.660 |
Why?
| | Betacoronavirus | 2 | 2020 | 286 | 0.650 |
Why?
| | Alopecia | 2 | 2012 | 37 | 0.650 |
Why?
| | Dermatitis, Allergic Contact | 4 | 2002 | 72 | 0.630 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2020 | 37 | 0.610 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2020 | 55 | 0.600 |
Why?
| | Exanthema | 1 | 2020 | 84 | 0.590 |
Why?
| | Isotretinoin | 2 | 2022 | 26 | 0.590 |
Why?
| | Diagnosis, Differential | 13 | 2015 | 1495 | 0.580 |
Why?
| | Ichthyosis | 3 | 2025 | 15 | 0.580 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 384 | 0.560 |
Why?
| | Coronavirus Infections | 2 | 2020 | 378 | 0.560 |
Why?
| | Skin Diseases | 3 | 2011 | 149 | 0.560 |
Why?
| | Pandemics | 4 | 2023 | 1695 | 0.550 |
Why?
| | Mandelic Acids | 1 | 2018 | 2 | 0.550 |
Why?
| | Parasympatholytics | 1 | 2018 | 11 | 0.550 |
Why?
| | Hyperhidrosis | 1 | 2018 | 7 | 0.540 |
Why?
| | Adolescent | 27 | 2025 | 22453 | 0.530 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 174 | 0.530 |
Why?
| | GTP-Binding Protein alpha Subunits | 2 | 2016 | 15 | 0.520 |
Why?
| | Male | 51 | 2026 | 72406 | 0.510 |
Why?
| | Dermatitis, Atopic | 2 | 2017 | 321 | 0.500 |
Why?
| | Education, Distance | 1 | 2017 | 61 | 0.500 |
Why?
| | Vascular Neoplasms | 2 | 2016 | 18 | 0.490 |
Why?
| | Female | 48 | 2026 | 78376 | 0.490 |
Why?
| | Child, Preschool | 21 | 2025 | 11799 | 0.490 |
Why?
| | Infant, Newborn | 15 | 2026 | 6434 | 0.480 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 58 | 0.470 |
Why?
| | Telemedicine | 2 | 2023 | 948 | 0.470 |
Why?
| | Histiocytosis | 1 | 2015 | 9 | 0.470 |
Why?
| | Epidermolysis Bullosa, Junctional | 3 | 2021 | 3 | 0.460 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 28 | 0.460 |
Why?
| | Mutation | 8 | 2026 | 4099 | 0.450 |
Why?
| | Alopecia Areata | 2 | 2022 | 13 | 0.440 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2015 | 36 | 0.440 |
Why?
| | Nevus, Pigmented | 1 | 2015 | 35 | 0.430 |
Why?
| | Rare Diseases | 1 | 2015 | 113 | 0.430 |
Why?
| | Wound Healing | 4 | 2025 | 351 | 0.430 |
Why?
| | Thrombocytopenia | 2 | 2016 | 205 | 0.430 |
Why?
| | Anemia | 5 | 2023 | 188 | 0.420 |
Why?
| | Endothelium, Lymphatic | 1 | 2014 | 11 | 0.420 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 23 | 0.420 |
Why?
| | Sweat Gland Neoplasms | 2 | 2011 | 8 | 0.410 |
Why?
| | Hydrops Fetalis | 1 | 2014 | 13 | 0.410 |
Why?
| | Drug Eruptions | 1 | 2013 | 28 | 0.400 |
Why?
| | Propranolol | 2 | 2011 | 44 | 0.400 |
Why?
| | Young Adult | 16 | 2025 | 14126 | 0.390 |
Why?
| | Hemangioendothelioma | 1 | 2012 | 13 | 0.380 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2012 | 8 | 0.380 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 157 | 0.370 |
Why?
| | Langer-Giedion Syndrome | 1 | 2012 | 2 | 0.360 |
Why?
| | Hair Diseases | 1 | 2012 | 10 | 0.360 |
Why?
| | Bone Demineralization, Pathologic | 1 | 2011 | 2 | 0.360 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2012 | 35 | 0.350 |
Why?
| | Clinical Competence | 3 | 2025 | 1244 | 0.350 |
Why?
| | Sarcoma, Kaposi | 1 | 2012 | 83 | 0.350 |
Why?
| | Calcification, Physiologic | 1 | 2011 | 29 | 0.350 |
Why?
| | Bone Diseases, Metabolic | 2 | 2011 | 56 | 0.340 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2014 | 452 | 0.340 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 418 | 0.340 |
Why?
| | Sulfones | 1 | 2012 | 127 | 0.340 |
Why?
| | Internship and Residency | 2 | 2022 | 1257 | 0.340 |
Why?
| | 2-Propanol | 1 | 2011 | 20 | 0.330 |
Why?
| | Facial Neoplasms | 1 | 2011 | 19 | 0.330 |
Why?
| | Facial Dermatoses | 2 | 2010 | 17 | 0.330 |
Why?
| | Dermis | 2 | 2011 | 32 | 0.330 |
Why?
| | Pediatrics | 2 | 2025 | 1115 | 0.330 |
Why?
| | Gene Deletion | 1 | 2012 | 389 | 0.330 |
Why?
| | Bone Density | 2 | 2011 | 482 | 0.330 |
Why?
| | Hyperpigmentation | 1 | 2011 | 27 | 0.330 |
Why?
| | Genes, Recessive | 3 | 2025 | 78 | 0.320 |
Why?
| | Solvents | 1 | 2011 | 113 | 0.320 |
Why?
| | Ferrochelatase | 1 | 2010 | 1 | 0.320 |
Why?
| | Porphyria, Erythropoietic | 1 | 2010 | 2 | 0.320 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2010 | 15 | 0.320 |
Why?
| | Desmoplakins | 1 | 2010 | 24 | 0.310 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2365 | 0.310 |
Why?
| | Tumor Burden | 1 | 2011 | 322 | 0.310 |
Why?
| | Xanthomatosis | 1 | 2009 | 8 | 0.310 |
Why?
| | Laryngeal Neoplasms | 1 | 2010 | 35 | 0.310 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1718 | 0.300 |
Why?
| | Mediastinal Neoplasms | 1 | 2010 | 51 | 0.300 |
Why?
| | Granuloma | 1 | 2010 | 96 | 0.300 |
Why?
| | Carcinoma | 2 | 2011 | 228 | 0.300 |
Why?
| | Piperazines | 1 | 2012 | 381 | 0.290 |
Why?
| | Parakeratosis | 1 | 2008 | 1 | 0.280 |
Why?
| | Pruritus | 3 | 2014 | 59 | 0.280 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 250 | 0.280 |
Why?
| | Treatment Outcome | 10 | 2025 | 11695 | 0.270 |
Why?
| | Canada | 3 | 2020 | 428 | 0.260 |
Why?
| | Self-Help Groups | 1 | 2007 | 37 | 0.260 |
Why?
| | Dermatitis, Exfoliative | 1 | 2006 | 3 | 0.250 |
Why?
| | Hand Dermatoses | 1 | 2006 | 7 | 0.250 |
Why?
| | Immunoglobulin A | 3 | 2018 | 214 | 0.240 |
Why?
| | Ethics, Medical | 1 | 2007 | 90 | 0.240 |
Why?
| | Pemphigus | 1 | 2005 | 8 | 0.230 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2022 | 642 | 0.230 |
Why?
| | Specialty Boards | 1 | 2025 | 42 | 0.230 |
Why?
| | Netherton Syndrome | 1 | 2025 | 3 | 0.220 |
Why?
| | Ichthyosiform Erythroderma, Congenital | 1 | 2025 | 6 | 0.220 |
Why?
| | Hamartoma | 1 | 2005 | 29 | 0.220 |
Why?
| | Skin Pigmentation | 1 | 2025 | 48 | 0.220 |
Why?
| | Prospective Studies | 4 | 2022 | 7997 | 0.220 |
Why?
| | Cost Savings | 1 | 2025 | 86 | 0.220 |
Why?
| | Phytotherapy | 1 | 2025 | 74 | 0.220 |
Why?
| | Biopsy, Needle | 3 | 2019 | 183 | 0.220 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1358 | 0.210 |
Why?
| | Incontinentia Pigmenti | 1 | 2004 | 3 | 0.210 |
Why?
| | Education, Medical, Continuing | 1 | 2025 | 132 | 0.210 |
Why?
| | Homozygote | 1 | 2025 | 199 | 0.210 |
Why?
| | Observer Variation | 4 | 2022 | 355 | 0.210 |
Why?
| | Certification | 1 | 2025 | 119 | 0.210 |
Why?
| | Adult | 18 | 2025 | 40506 | 0.210 |
Why?
| | Biopsy | 3 | 2015 | 1077 | 0.210 |
Why?
| | Transcription Factors | 1 | 2012 | 1742 | 0.210 |
Why?
| | Sarcoma, Clear Cell | 1 | 2024 | 9 | 0.210 |
Why?
| | Introns | 1 | 2025 | 254 | 0.200 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2024 | 80 | 0.200 |
Why?
| | Scalp | 1 | 2024 | 37 | 0.200 |
Why?
| | North America | 3 | 2021 | 310 | 0.200 |
Why?
| | Immunoglobulin G | 3 | 2018 | 893 | 0.200 |
Why?
| | Plant Extracts | 1 | 2025 | 187 | 0.200 |
Why?
| | Administration, Topical | 3 | 2020 | 150 | 0.200 |
Why?
| | Aspirin | 1 | 2006 | 400 | 0.200 |
Why?
| | Water | 1 | 2006 | 469 | 0.200 |
Why?
| | Genetic Association Studies | 1 | 2025 | 373 | 0.190 |
Why?
| | Privacy | 1 | 2023 | 41 | 0.190 |
Why?
| | Triterpenes | 1 | 2023 | 25 | 0.190 |
Why?
| | Transition to Adult Care | 1 | 2024 | 96 | 0.190 |
Why?
| | Phenotype | 3 | 2025 | 3164 | 0.190 |
Why?
| | Confidentiality | 1 | 2023 | 79 | 0.190 |
Why?
| | Retrospective Studies | 13 | 2025 | 17101 | 0.190 |
Why?
| | Decision Support Techniques | 1 | 2007 | 456 | 0.190 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2006 | 497 | 0.190 |
Why?
| | Skin Care | 2 | 2020 | 25 | 0.180 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 16 | 0.180 |
Why?
| | Middle Aged | 11 | 2025 | 35928 | 0.180 |
Why?
| | Competency-Based Education | 1 | 2022 | 79 | 0.170 |
Why?
| | Consensus | 3 | 2024 | 489 | 0.170 |
Why?
| | Jews | 1 | 2021 | 20 | 0.170 |
Why?
| | Cohort Studies | 4 | 2022 | 5965 | 0.170 |
Why?
| | Administration, Intravenous | 1 | 2022 | 170 | 0.170 |
Why?
| | Biological Products | 1 | 2025 | 252 | 0.170 |
Why?
| | Rhabdomyosarcoma | 1 | 2022 | 64 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2014 | 479 | 0.170 |
Why?
| | Fatal Outcome | 2 | 2014 | 307 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2024 | 276 | 0.170 |
Why?
| | Quality of Life | 4 | 2025 | 3192 | 0.170 |
Why?
| | Anesthetics | 1 | 2022 | 99 | 0.170 |
Why?
| | Toes | 1 | 2020 | 16 | 0.160 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 356 | 0.160 |
Why?
| | NF-kappa B | 1 | 2004 | 662 | 0.160 |
Why?
| | Absorptiometry, Photon | 2 | 2011 | 276 | 0.160 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5417 | 0.160 |
Why?
| | Detergents | 1 | 2020 | 44 | 0.160 |
Why?
| | Mycoplasma pneumoniae | 1 | 2020 | 53 | 0.150 |
Why?
| | Mouth Diseases | 2 | 2013 | 46 | 0.150 |
Why?
| | Mouth Mucosa | 2 | 2013 | 88 | 0.150 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 412 | 0.150 |
Why?
| | Prenatal Diagnosis | 2 | 2014 | 195 | 0.150 |
Why?
| | Iron | 3 | 2023 | 359 | 0.150 |
Why?
| | APOBEC Deaminases | 1 | 2018 | 6 | 0.140 |
Why?
| | Cytosine Deaminase | 1 | 2018 | 15 | 0.140 |
Why?
| | Linear IgA Bullous Dermatosis | 1 | 2018 | 1 | 0.140 |
Why?
| | Palliative Care | 1 | 2007 | 1008 | 0.140 |
Why?
| | Dilatation | 1 | 2018 | 72 | 0.140 |
Why?
| | Esophageal Stenosis | 1 | 2018 | 57 | 0.140 |
Why?
| | Administration, Oral | 2 | 2012 | 848 | 0.140 |
Why?
| | Fluoroscopy | 1 | 2018 | 176 | 0.140 |
Why?
| | Chronic Pain | 1 | 2022 | 292 | 0.140 |
Why?
| | Age Distribution | 1 | 2019 | 403 | 0.140 |
Why?
| | Sex Distribution | 1 | 2019 | 386 | 0.130 |
Why?
| | Patient Satisfaction | 1 | 2022 | 705 | 0.130 |
Why?
| | Cost of Illness | 1 | 2020 | 321 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 557 | 0.130 |
Why?
| | Esophagoscopy | 1 | 2018 | 221 | 0.130 |
Why?
| | Surveys and Questionnaires | 5 | 2024 | 6053 | 0.120 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 32 | 0.120 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2016 | 19 | 0.120 |
Why?
| | Databases, Factual | 2 | 2020 | 1486 | 0.120 |
Why?
| | Staphylococcal Infections | 1 | 2020 | 390 | 0.120 |
Why?
| | Incidence | 2 | 2022 | 2883 | 0.120 |
Why?
| | United States | 5 | 2025 | 15988 | 0.120 |
Why?
| | Risk Assessment | 3 | 2019 | 3676 | 0.110 |
Why?
| | Survival Analysis | 1 | 2019 | 1385 | 0.110 |
Why?
| | Clobetasol | 1 | 2015 | 7 | 0.110 |
Why?
| | Pachyonychia Congenita | 1 | 2015 | 4 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 292 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2022 | 683 | 0.110 |
Why?
| | Double-Blind Method | 3 | 2025 | 2029 | 0.110 |
Why?
| | Patient Care Team | 1 | 2020 | 689 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 311 | 0.110 |
Why?
| | Keratins | 1 | 2015 | 172 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 186 | 0.100 |
Why?
| | Antigens, CD34 | 1 | 2014 | 88 | 0.100 |
Why?
| | Prednisolone | 2 | 2013 | 66 | 0.100 |
Why?
| | Photography | 2 | 2025 | 115 | 0.100 |
Why?
| | Disease Progression | 2 | 2019 | 2852 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 3 | 2014 | 475 | 0.100 |
Why?
| | Pemphigoid, Bullous | 1 | 2013 | 7 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1990 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 2 | 2021 | 370 | 0.090 |
Why?
| | Remission, Spontaneous | 1 | 2012 | 40 | 0.090 |
Why?
| | Skin Diseases, Papulosquamous | 1 | 2012 | 2 | 0.090 |
Why?
| | Erythema | 3 | 2022 | 28 | 0.090 |
Why?
| | Prednisone | 2 | 2005 | 221 | 0.090 |
Why?
| | Transcriptome | 2 | 2018 | 1046 | 0.090 |
Why?
| | Oropharynx | 1 | 2012 | 46 | 0.090 |
Why?
| | Sildenafil Citrate | 1 | 2012 | 60 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1890 | 0.090 |
Why?
| | Panniculitis | 1 | 2011 | 3 | 0.090 |
Why?
| | Actins | 1 | 2014 | 425 | 0.090 |
Why?
| | Carcinoma, Verrucous | 1 | 2011 | 3 | 0.090 |
Why?
| | Fractures, Compression | 1 | 2011 | 15 | 0.090 |
Why?
| | Nose | 1 | 2012 | 68 | 0.090 |
Why?
| | Age Determination by Skeleton | 1 | 2011 | 16 | 0.090 |
Why?
| | Blood Sedimentation | 1 | 2011 | 37 | 0.090 |
Why?
| | Dwarfism | 1 | 2011 | 15 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 31 | 0.080 |
Why?
| | Fingers | 1 | 2012 | 107 | 0.080 |
Why?
| | Subcutaneous Fat | 1 | 2011 | 78 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2025 | 3415 | 0.080 |
Why?
| | Spinal Fractures | 1 | 2011 | 73 | 0.080 |
Why?
| | Mobility Limitation | 1 | 2011 | 66 | 0.080 |
Why?
| | Caregivers | 1 | 2020 | 1049 | 0.080 |
Why?
| | Purines | 1 | 2012 | 187 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 535 | 0.080 |
Why?
| | Darier Disease | 1 | 2010 | 2 | 0.080 |
Why?
| | Body Size | 1 | 2011 | 95 | 0.080 |
Why?
| | Vincristine | 1 | 2011 | 140 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2015 | 2832 | 0.080 |
Why?
| | Serum Albumin | 1 | 2011 | 147 | 0.080 |
Why?
| | Autoantibodies | 1 | 2018 | 1504 | 0.080 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2010 | 33 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2011 | 1048 | 0.080 |
Why?
| | Body Height | 1 | 2011 | 202 | 0.080 |
Why?
| | Steroids | 1 | 2011 | 160 | 0.080 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 96 | 0.080 |
Why?
| | Porphyrins | 1 | 2010 | 16 | 0.080 |
Why?
| | Patch Tests | 2 | 2001 | 57 | 0.080 |
Why?
| | Keratinocytes | 2 | 2024 | 250 | 0.080 |
Why?
| | Clarithromycin | 1 | 2010 | 25 | 0.080 |
Why?
| | Consanguinity | 1 | 2010 | 49 | 0.080 |
Why?
| | Sequence Analysis, DNA | 2 | 2010 | 824 | 0.080 |
Why?
| | Erythromycin | 1 | 2010 | 20 | 0.080 |
Why?
| | Infant, Newborn, Diseases | 1 | 2011 | 113 | 0.080 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1915 | 0.080 |
Why?
| | Foam Cells | 1 | 2009 | 17 | 0.080 |
Why?
| | Ointments | 2 | 2023 | 25 | 0.080 |
Why?
| | Porokeratosis | 1 | 2009 | 1 | 0.080 |
Why?
| | Nevus, Intradermal | 1 | 2009 | 3 | 0.080 |
Why?
| | Keratosis | 1 | 2009 | 16 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2010 | 193 | 0.080 |
Why?
| | Staining and Labeling | 1 | 2010 | 151 | 0.070 |
Why?
| | Respiratory Sounds | 1 | 2010 | 105 | 0.070 |
Why?
| | Radiography | 1 | 2012 | 845 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 676 | 0.070 |
Why?
| | Epidermodysplasia Verruciformis | 1 | 2009 | 1 | 0.070 |
Why?
| | Basement Membrane | 2 | 2007 | 32 | 0.070 |
Why?
| | Lumbar Vertebrae | 1 | 2011 | 252 | 0.070 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2011 | 319 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2011 | 417 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1416 | 0.070 |
Why?
| | Dapsone | 2 | 2005 | 8 | 0.070 |
Why?
| | Hemoglobins | 1 | 2011 | 384 | 0.070 |
Why?
| | Diaper Rash | 1 | 2008 | 5 | 0.070 |
Why?
| | Blister | 3 | 2013 | 39 | 0.070 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2010 | 194 | 0.070 |
Why?
| | Immune System Diseases | 1 | 2008 | 39 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2010 | 162 | 0.070 |
Why?
| | Psychophysiologic Disorders | 1 | 2007 | 11 | 0.070 |
Why?
| | Hair | 1 | 2008 | 88 | 0.070 |
Why?
| | Aged | 4 | 2025 | 25947 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2011 | 582 | 0.070 |
Why?
| | Weight Gain | 1 | 2011 | 559 | 0.070 |
Why?
| | Anti-Anxiety Agents | 1 | 2007 | 45 | 0.070 |
Why?
| | Euthanasia, Passive | 1 | 2007 | 3 | 0.060 |
Why?
| | Ethics Committees | 1 | 2007 | 3 | 0.060 |
Why?
| | Biomedical Research | 1 | 2014 | 710 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 965 | 0.060 |
Why?
| | Androgens | 1 | 2008 | 186 | 0.060 |
Why?
| | Hematinics | 1 | 2006 | 22 | 0.060 |
Why?
| | Patient Advocacy | 1 | 2007 | 74 | 0.060 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 197 | 0.060 |
Why?
| | Ferric Compounds | 1 | 2006 | 55 | 0.060 |
Why?
| | Erythropoietin | 1 | 2006 | 100 | 0.060 |
Why?
| | Professional-Family Relations | 1 | 2007 | 153 | 0.060 |
Why?
| | Desmoglein 3 | 1 | 2005 | 14 | 0.060 |
Why?
| | Dermatologists | 1 | 2025 | 7 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2007 | 248 | 0.060 |
Why?
| | Plant Bark | 1 | 2025 | 11 | 0.060 |
Why?
| | California | 1 | 2007 | 475 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 214 | 0.060 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2005 | 17 | 0.060 |
Why?
| | Social Environment | 1 | 2007 | 254 | 0.060 |
Why?
| | Colonic Diseases | 1 | 2005 | 34 | 0.060 |
Why?
| | Cellulitis | 1 | 2005 | 53 | 0.060 |
Why?
| | Physicians | 1 | 2014 | 940 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2007 | 313 | 0.060 |
Why?
| | Calcium | 1 | 2011 | 1184 | 0.060 |
Why?
| | Dermatitis Herpetiformis | 1 | 2004 | 2 | 0.050 |
Why?
| | Fibroblasts | 2 | 2024 | 1034 | 0.050 |
Why?
| | Epidermis | 1 | 2005 | 157 | 0.050 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 847 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2011 | 783 | 0.050 |
Why?
| | Urticaria | 1 | 2004 | 38 | 0.050 |
Why?
| | Skin Transplantation | 1 | 2024 | 85 | 0.050 |
Why?
| | Neutrophils | 1 | 2009 | 1134 | 0.050 |
Why?
| | Anthraquinones | 1 | 2023 | 10 | 0.050 |
Why?
| | Gene Editing | 1 | 2024 | 93 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 54 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 292 | 0.050 |
Why?
| | Betula | 1 | 2023 | 3 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 851 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 403 | 0.050 |
Why?
| | Catastrophization | 1 | 2022 | 16 | 0.050 |
Why?
| | Eosinophilia | 1 | 2005 | 221 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2002 | 24 | 0.050 |
Why?
| | Pregnancy | 2 | 2014 | 7191 | 0.050 |
Why?
| | Needs Assessment | 1 | 2025 | 404 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 170 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2023 | 86 | 0.050 |
Why?
| | Social Support | 1 | 2007 | 652 | 0.050 |
Why?
| | Family | 1 | 2007 | 679 | 0.050 |
Why?
| | Mucous Membrane | 2 | 2014 | 127 | 0.050 |
Why?
| | Autoantigens | 1 | 2005 | 429 | 0.050 |
Why?
| | Professionalism | 1 | 2022 | 26 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1839 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 331 | 0.050 |
Why?
| | Atrophy | 2 | 2013 | 201 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 101 | 0.040 |
Why?
| | Germ Cells | 1 | 2022 | 66 | 0.040 |
Why?
| | Chile | 1 | 2021 | 26 | 0.040 |
Why?
| | Colombia | 1 | 2021 | 42 | 0.040 |
Why?
| | Prevalence | 2 | 2022 | 2836 | 0.040 |
Why?
| | Blood Protein Electrophoresis | 1 | 1981 | 6 | 0.040 |
Why?
| | Social Class | 1 | 2023 | 268 | 0.040 |
Why?
| | Nephelometry and Turbidimetry | 1 | 1981 | 15 | 0.040 |
Why?
| | Mupirocin | 1 | 2020 | 7 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5872 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 467 | 0.040 |
Why?
| | Information Dissemination | 1 | 2023 | 223 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2022 | 189 | 0.040 |
Why?
| | Mexico | 1 | 2021 | 233 | 0.040 |
Why?
| | Retinoids | 1 | 2020 | 33 | 0.040 |
Why?
| | Parents | 2 | 2022 | 1403 | 0.040 |
Why?
| | Immunoglobulins | 1 | 1981 | 160 | 0.040 |
Why?
| | Cosmetics | 1 | 2020 | 8 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1835 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 282 | 0.040 |
Why?
| | Language | 1 | 2023 | 323 | 0.040 |
Why?
| | Inflammation | 1 | 2011 | 2880 | 0.040 |
Why?
| | Mutation Rate | 1 | 2018 | 30 | 0.040 |
Why?
| | Desmocollins | 1 | 2018 | 2 | 0.040 |
Why?
| | Desmogleins | 1 | 2018 | 3 | 0.040 |
Why?
| | Age of Onset | 1 | 2000 | 551 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 183 | 0.030 |
Why?
| | Mutagenesis | 1 | 2018 | 192 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3869 | 0.030 |
Why?
| | Self Care | 1 | 2020 | 389 | 0.030 |
Why?
| | Esophagus | 1 | 2018 | 261 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2024 | 2050 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2020 | 460 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1186 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 748 | 0.030 |
Why?
| | Melanocytes | 1 | 2016 | 65 | 0.030 |
Why?
| | DNA Repair | 1 | 2018 | 256 | 0.030 |
Why?
| | Pain | 2 | 2015 | 782 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 3335 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 108 | 0.030 |
Why?
| | Alemtuzumab | 1 | 2015 | 15 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2015 | 23 | 0.030 |
Why?
| | Vidarabine | 1 | 2015 | 32 | 0.030 |
Why?
| | Busulfan | 1 | 2015 | 16 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 947 | 0.030 |
Why?
| | Keratin-16 | 1 | 2015 | 1 | 0.030 |
Why?
| | Keratin-6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Keratin-17 | 1 | 2015 | 4 | 0.030 |
Why?
| | Skin Cream | 1 | 2014 | 11 | 0.030 |
Why?
| | Oils | 1 | 2014 | 22 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 768 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 69 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 381 | 0.030 |
Why?
| | Enzymes | 1 | 2015 | 65 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 415 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 437 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 1177 | 0.030 |
Why?
| | Oral Medicine | 1 | 2013 | 1 | 0.030 |
Why?
| | Lip Diseases | 1 | 2013 | 7 | 0.020 |
Why?
| | Hospitalization | 1 | 2024 | 2434 | 0.020 |
Why?
| | Tongue Diseases | 1 | 2013 | 9 | 0.020 |
Why?
| | HIV Infections | 1 | 2009 | 3154 | 0.020 |
Why?
| | Palate | 1 | 2013 | 39 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 758 | 0.020 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 1992 | 11 | 0.020 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 1992 | 19 | 0.020 |
Why?
| | Microstomia | 1 | 2012 | 1 | 0.020 |
Why?
| | Mouth Abnormalities | 1 | 2012 | 2 | 0.020 |
Why?
| | Ankyloglossia | 1 | 2012 | 2 | 0.020 |
Why?
| | Down-Regulation | 1 | 2015 | 627 | 0.020 |
Why?
| | Dental Enamel Hypoplasia | 1 | 2012 | 9 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1563 | 0.020 |
Why?
| | Ulcer | 1 | 2012 | 37 | 0.020 |
Why?
| | Risk Factors | 1 | 2006 | 10792 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1462 | 0.020 |
Why?
| | Back | 1 | 2011 | 12 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 852 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 465 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1268 | 0.020 |
Why?
| | Cicatrix | 1 | 2012 | 69 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.020 |
Why?
| | Therapeutics | 1 | 2011 | 14 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 427 | 0.020 |
Why?
| | Animals | 2 | 2024 | 38109 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 1992 | 509 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 244 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 589 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 177 | 0.020 |
Why?
| | Elastic Tissue | 1 | 2009 | 10 | 0.020 |
Why?
| | Hair Follicle | 1 | 2009 | 48 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2011 | 331 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 409 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 988 | 0.020 |
Why?
| | Exons | 1 | 2010 | 358 | 0.020 |
Why?
| | Neck | 1 | 2009 | 108 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2015 | 1126 | 0.020 |
Why?
| | Arm | 1 | 2009 | 110 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 4155 | 0.020 |
Why?
| | Resuscitation | 1 | 2011 | 302 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2014 | 853 | 0.020 |
Why?
| | Preimplantation Diagnosis | 1 | 2007 | 6 | 0.020 |
Why?
| | Skin Diseases, Genetic | 1 | 2007 | 13 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1786 | 0.020 |
Why?
| | Heart Arrest | 1 | 2011 | 407 | 0.020 |
Why?
| | Darbepoetin alfa | 1 | 2006 | 3 | 0.020 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2007 | 59 | 0.020 |
Why?
| | Mice | 1 | 2024 | 18365 | 0.020 |
Why?
| | Wound Infection | 1 | 2007 | 57 | 0.020 |
Why?
| | Malnutrition | 1 | 2007 | 86 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4293 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8279 | 0.010 |
Why?
| | Fetal Diseases | 1 | 2007 | 191 | 0.010 |
Why?
| | Syndrome | 1 | 2005 | 380 | 0.010 |
Why?
| | Primary Health Care | 1 | 2014 | 1734 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 338 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 2313 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1981 | 284 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1813 | 0.010 |
Why?
| | Proto-Oncogenes | 1 | 1992 | 29 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1992 | 2032 | 0.000 |
Why?
| | Cell Line | 1 | 1992 | 2882 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1992 | 931 | 0.000 |
Why?
| | Cytokines | 1 | 1992 | 2065 | 0.000 |
Why?
|
|
Bruckner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|